149 related articles for article (PubMed ID: 34784097)
21. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Fléchon A; Pouessel D; Ferlay C; Perol D; Beuzeboc P; Gravis G; Joly F; Oudard S; Deplanque G; Zanetta S; Fargeot P; Priou F; Droz JP; Culine S
Ann Oncol; 2011 Nov; 22(11):2476-2481. PubMed ID: 21436186
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.
Krauss DJ; Hayek S; Amin M; Ye H; Kestin LL; Zadora S; Vicini FA; Cotant M; Brabbins DS; Ghilezan MI; Gustafson GS; Martinez AA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e119-25. PubMed ID: 21596486
[TBL] [Abstract][Full Text] [Related]
24. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
25. Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients.
Sawaki M; Yokoi K; Nagasaka T; Watanabe R; Kagawa C; Takada H; Sato S; Yamada T; Kikumori T; Imai T; Nakao A
Surg Today; 2010 Sep; 40(9):831-5. PubMed ID: 20740345
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples.
Speights VO; Cohen MK; Riggs MW; Coffield KS; Keegan G; Arber DA
Br J Urol; 1997 Aug; 80(2):281-6. PubMed ID: 9284203
[TBL] [Abstract][Full Text] [Related]
27. Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
Kriegsmann K; Zgorzelski C; Muley T; Christopoulos P; Thomas M; Winter H; Eichhorn M; Eichhorn F; von Winterfeld M; Herpel E; Goeppert B; Stenzinger A; Herth FJF; Warth A; Kriegsmann M
BMC Cancer; 2021 May; 21(1):486. PubMed ID: 33933015
[TBL] [Abstract][Full Text] [Related]
28. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
[TBL] [Abstract][Full Text] [Related]
29. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine phenotype of non-small cell lung carcinoma: immunohistological evaluation and biochemical study.
Slodkowska J; Zych J; Szturmowicz M; Demkow U; Rowinska-Zakrzewska E; Roszkowski-Sliz K
Int J Biol Markers; 2005; 20(4):217-26. PubMed ID: 16398403
[TBL] [Abstract][Full Text] [Related]
32. Correlation between chromogranin A, neuron-specific enolase and synaptophysin expression, and some clinico-pathological features of colorectal cancer.
Famulski W; Sulkowska M; Miller-Famulska D; Kisielewski W; Sulkowski S
Folia Histochem Cytobiol; 2001; 39(2):155-6. PubMed ID: 11374802
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine marker expression in cervical carcinomas of non-small cell type.
Chavez-Blanco A; Taja-Chayeb L; Cetina L; Chanona-Vilchis G; Trejo-Becerril C; Perez-Cardenas E; Segura-Pacheco B; Acuña-González C; Dueñas-Gonzalez A
Int J Gynecol Pathol; 2002 Oct; 21(4):368-74. PubMed ID: 12352185
[TBL] [Abstract][Full Text] [Related]
34. Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A.
Lai M; Lü B; Xing X; Xu E; Ren G; Huang Q
Virchows Arch; 2006 Oct; 449(4):402-9. PubMed ID: 16955307
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of neuroendocrine markers in renal cell carcinoma.
Ronkainen H; Soini Y; Vaarala MH; Kauppila S; Hirvikoski P
Diagn Pathol; 2010 May; 5():28. PubMed ID: 20462442
[TBL] [Abstract][Full Text] [Related]
36. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
Petrović M; Ilić N; Baskić D
Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
[TBL] [Abstract][Full Text] [Related]
37. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
38. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
39. The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer.
Xiang Q; Zhu Z; Luo L; Wang J; Liu Y; Deng Y; Zhou M; Zhao Z
Biomed Res Int; 2020; 2020():5395312. PubMed ID: 33029516
[TBL] [Abstract][Full Text] [Related]
40. Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
Kardoust Parizi M; Iwata T; Kimura S; Janisch F; Abufaraj M; Karakiewicz PI; Enikeev D; Rapoport LM; Hutterer G; Shariat SF
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]